Chapter 027

Drugs Acting on the Respiratory System

Karen S. Gregson and Jeffrey D. Bennett

GENERAL REFERENCES

  1. Barnes PJ: Theophylline: new perspectives for an old drug, Am. J. Respir. Crit. Care Med 167:813–818, 2003. PUBMED Abstract
  2. Caramori G, et al.: Molecular pathogenesis of cigarette smoking–induced stable COPD, Annals of the New York Academy of Sciences, 2015. PUBMED Abstract
  3. Deakins KM: Year in Review 2014: Asthma, Respiratory Care 60:744–748, 2015. PUBMED Abstract
  4. Frith PA, et al.: Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study—a randomised controlled trial, Thorax, 2015. PUBMED Abstract
  5. Latorre M, et al.: Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS, Pulmonary Pharmacology & Therapeutics 30:44–50, 2015. PUBMED Abstract
  6. Navarrete BA, et al.: “Correct Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease”: A Consensus Document, Archivos de Bronconeumología (English Edition) 51:193–198, 2015. PUBMED Abstract
  7. Naycı, S.A., et al. “Updates in Chronic Obstructive Pulmonary Disease for the Year 2014.” 2015.
  8. O’Quinn JW, et al.: Omalizumab Treatment of Moderate to Severe Asthma in the Adolescent and Pediatric Population, Journal of Allergy and Clinical Immunology 135.2, 2015. Abs. 3.
  9. Patel M, Shaw D: A review of standard pharmacological therapy for adult asthma–Steps 1 to 5, Chronic Respiratory Disease 12:165–176, 2015. PUBMED Abstract
  10. Stelmach I, et al.: Do children with stable asthma benefit from addition of montelukast to inhaled corticosteroids: Randomized, placebo controlled trial, Pulmonary Pharmacology & Therapeutics 31:42–48, 2015. PUBMED Abstract